-
Study aim
-
Determination the effect of zinc gluconate supplementation on the serum levels of IL-35, C-reactive protein, oxidative stress status, spirometry test and clinical symptoms in patients with mild and moderate persistent allergic asthma.
-
Design
-
A clinical trial with control group including a sample size of 62 people,with parallel group, double-blind, randomized
-
Settings and conduct
-
Referred to the Ahvaz Asthma and Allergy Clinic in 2022, selection of 62 patients based on inclusion and exclusion criteria, randomization into intervention and control groups. Blinding of patients and researchers, coding by a third party who does not know the details.
-
Participants/Inclusion and exclusion criteria
-
Ages 18 to 65 years, Mild to moderate persistent allergic asthma, Body mass index: 18.5-30 kg/m2;Non-inclusion criteria: smoking, Pregnancy and lactation, Cardiovascular diseases and other chronic diseases, Use of antioxidant or zinc supplements in the last three months, Not wanting to continue cooperation
-
Intervention groups
-
Study groups include zinc gluconate and placebo consumer groups
-
Main outcome variables
-
IL-35; TAC; FEV1, FVC, FEV1/FVC